| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 276 | 2020 |
| Allogeneic CAR-T cells: more than ease of access? C Graham, A Jozwik, A Pepper, R Benjamin Cells 7 (10), 155, 2018 | 172 | 2018 |
| Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with … R Benjamin, C Graham, D Yallop, A Jozwik, O Ciocarlie, N Jain, ... Blood 132, 896, 2018 | 87 | 2018 |
| Cancer immunotherapy with CAR-T cells–behold the future C Graham, R Hewitson, A Pagliuca, R Benjamin Clinical Medicine 18 (4), 324, 2018 | 63 | 2018 |
| UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a … R Benjamin, N Jain, MV Maus, N Boissel, C Graham, A Jozwik, D Yallop, ... The Lancet Haematology 9 (11), e833-e843, 2022 | 51 | 2022 |
| COVID-19 in patients with sickle cell disease–a case series from a UK tertiary hospital S Chakravorty, G Padmore-Payne, F Ike, V Tshibangu, C Graham, D Rees, ... Haematologica 105 (11), 2691, 2020 | 40 | 2020 |
| Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation S Chitre, F Stölzel, K Cuthill, M Streetly, C Graham, C Dill, A Mohamedali, ... Leukemia 32 (9), 2020-2024, 2018 | 29 | 2018 |
| Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed/refractory B-cell acute … C Graham, D Yallop, A Jozwik, P Patten, A Dunlop, R Ellard, O Stewart, ... Blood 130, 887, 2017 | 20 | 2017 |
| Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma CE Graham, A Jozwik, R Quartey-Papafio, N Ioannou, AM Metelo, ... Leukemia 35 (12), 3581-3584, 2021 | 18 | 2021 |
| Four challenges to CAR T cells breaking the glass ceiling SR Bailey, TR Berger, C Graham, RC Larson, MV Maus European Journal of Immunology 53 (11), 2250039, 2023 | 16 | 2023 |
| Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma B Apollonio, F Spada, N Petrov, D Cozzetto, D Papazoglou, P Jarvis, ... The Journal of clinical investigation 133 (13), 2023 | 14 | 2023 |
| Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity CE Graham, WH Lee, HR Wiggin, VM Supper, MB Leick, F Birocchi, ... Blood, 2023 | 13 | 2023 |
| Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors AM Metelo, A Jozwik, LA Luong, D Dominey-Foy, C Graham, C Attwood, ... Cancer Research Communications 2 (3), 158-171, 2022 | 13 | 2022 |
| Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T cell product, in adult B-cell acute lymphoblastic leukemia S Dupouy, I Marchiq, T Derippe, M Almena-Carrasco, A Jozwik, ... Cancer Research Communications 2 (11), 1520-1531, 2022 | 10 | 2022 |
| UCART19, an allogeneic anti-CD19 CAR T-cell product, in high risk adult patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia: preliminary results of … N Jain, C Graham, M Konopleva, D Yallop, A Jozwik, P Patten, R Ellard, ... learningcenter. ehaweb. org/ eha/ 2018/ stockholm/ 214674/ reuben. benjamin …, 2018 | 7 | 2018 |
| Allogeneic anti-CD19 CAR T cells manufactured from healthy donors provide a unique cellular product with distinct phenotypic characteristics compared to CAR T cells generated … C Graham, A Jozwik, R Quartey-Papafio, N Ioannou, AM Metelo, C Scala, ... Blood 134, 3228, 2019 | 5 | 2019 |
| Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding RJ Stapley, NS Poulter, AO Khan, CW Smith, P Bignell, C Fratter, ... Journal of Thrombosis and Haemostasis 20 (2), 478-485, 2022 | 4 | 2022 |
| Allogeneic anti-Bcma CAR-T cells show tumour specific killing against primary multiple myeloma cells from different genomic sub-groups AM Metelo, I Walker, A Jozwik, C Graham, C Attwood, K Sanchez, ... Blood 134, 1834, 2019 | 4 | 2019 |
| Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma RC Larson, MC Kann, C Graham, CW Mount, AP Castano, WH Lee, ... Nature Communications 14 (1), 7509, 2023 | 3 | 2023 |
| CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment CE Graham, MV Maus Blood Cancer Discovery 3 (6), 478-480, 2022 | 3 | 2022 |
